Sex determination and disorders of sex development according to the revised nomenclature and classification in 46,XX individuals

Hormones

Volumn 9, Issue 3, 2010, Pages 218-231

  Kousta, Eleni ^a   Papathanasiou, Asteroula ^a   Skordis, Nicos ^b  

^a P AND A KYRIAKOU CHILDREN S HOSPITAL   (Greece)

^b Pediatric Endocrine Unit   (Cyprus)

Author keywords

Androgen excess; Congenital adrenal hyperplasia; Disorders of sex development; Embryology of the ovary; Gonadal dysgenesis; Ovarian development

Indexed keywords

AROMATASE; BONE MORPHOGENETIC PROTEIN 15; CORTICOTROPIN; CYTOCHROME P450 REDUCTASE; FOLLITROPIN RECEPTOR; FRAGILE X MENTAL RETARDATION PROTEIN; GLUCOCORTICOID RECEPTOR; HYDROCORTISONE; NUCLEAR RECEPTOR DAX 1; PROTEIN FOXL2; PROTEIN RSPO1; STEROID 11BETA MONOOXYGENASE; STEROID 21 MONOOXYGENASE; STEROIDOGENIC FACTOR 1; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR SOX9; UNCLASSIFIED DRUG; WNT4 PROTEIN; WT1 PROTEIN;

CONGENITAL ADRENAL HYPERPLASIA; DISEASE CLASSIFICATION; DISORDERS OF SEX DEVELOPMENT; EMBRYOLOGY; GENETIC REGULATION; GONADAL DYSGENESIS; HUMAN; KARYOTYPE 46,XX; LUTEOMA; MOLECULAR BIOLOGY; MUTATIONAL ANALYSIS; NOMENCLATURE; OVARY DEVELOPMENT; P450 OXIDOREDUCTASE DEFICIENCY; REVIEW; ROKITANSKY SYNDROME; SEX DETERMINATION; SEX DIFFERENTIATION DISORDER; SIGNAL TRANSDUCTION; STEROID 21 MONOOXYGENASE DEFICIENCY; TRUE HERMAPHRODITISM; VAGINA ATRESIA; XX MALE; CLASSIFICATION; CONGENITAL MALFORMATION; FEMALE; GENDER AND SEX; GENE EXPRESSION REGULATION; GENETICS; GENITAL SYSTEM; GENOTYPE; KARYOTYPING; MALE; PATHOPHYSIOLOGY; PHENOTYPE; SEXUAL DEVELOPMENT; X CHROMOSOME;

CHROMOSOMES, HUMAN, X; FEMALE; GENE EXPRESSION REGULATION, DEVELOPMENTAL; GENITALIA; GENOTYPE; GONADAL DYSGENESIS, 46,XX; HUMANS; KARYOTYPING; MALE; PHENOTYPE; SEX DETERMINATION (ANALYSIS); SEX DETERMINATION (GENETICS); SEXUAL DEVELOPMENT; TERMINOLOGY AS TOPIC;

EID: 77956294339     PISSN: 11093099     EISSN: None     Source Type: Journal    
DOI: 10.14310/horm.2002.1272     Document Type: Review

References (93)

1. MacLaughlin DT, Donahoe PK, 2004 Sex determination and differentiation. N Engl J Med 350: 367-378.
2. Hughes IA, 2004 Female Development - All by Default? N Engl J Med 351: 748-750.
3. Hughes IA, Houk C, Ahmed SF, Lee PA, LWPES Consensus Group, ESPE Consensus Group, 2006 Consensus statement on management of intersex disorders. Arch Dis Child 91: 554-563.
4. Dacou-Voutetakis C, 2007 A multidisciplinary approach to the management of children with complex genital anomalies. Nat Clin Pract Endocrinol Metab 3: 668-669.
5. Sadler TW, 2006 Third to eight weeks: The embryonic period. In: Lippincott Williams & Wilkins, (eds) Langman's Medical Embryology 10th edition, Baltimore, Maryland, USA; pp, 67-87.
6. Sadler TW, 2006 Urogenital system. In: Lippincott Williams & Wilkins (eds) Langman's Medical Embryology 10th edition, Baltimore, Maryland, USA; pp, 229-256.
7. Sadler TW, 2006 Gametogenesis: Conversion of germ cells into male and female gametes. In: Lippincott Williams & Wilkins (eds) Langman's Medical Embryology 10th edition, Baltimore, Maryland, USA; pp, 11-29.
8. Wilhelm D, Palmer S, Koopman P, 2007 Sex determination and gonadal development in mammals. Physiol Rev 87: 1-28.
9. Barbosa A S, Hadjiathanasiou C G, Theodoridis C, et al, 1999 The same mutation affecting the splicing of WT1 gene is present on Frasier syndrome patients with or without Wilms' tumor. Hum Mutat 13: 146-153.
10. Jaubert F, Vasiliu V, Patey-Mariaud de Serre N, et al, 2003 Gonad development in Drash and Frasier syndromes depends on WT1 mutations. Arkh Patol 65: 40-44.
11. Demmer L, Primack W, Loik V, Brown R, Therville N, McElreavey K, 1999 Frasier syndrome: a cause of focal segmental glomerulosclerosis in a 46,XX female. J Am Soc Nephrol 10: 2215-2218.
12. Parker KL, Rice DA, Lala DS, et al, 2002 Steroidogenic factor 1: an essential mediator of endocrine development. Recent Prog Horm Res 57: 19-36.
13. Lala DS, Rice DA, Parker KL, 1992 Steroidogenic factor I, a key regulator of steroidogenic enzyme expression, is the mouse homolog of fushi tarazu-factor I. Mol Endocrinol 6: 1249-1258.
14. Mallet D, Bretones P, Michel-Calemard L, Dijoud F, David M, Morel Y, 2004 Gonadal dysgenesis without adrenal insufficiency in a 46,XY patient heterozygous for the nonsense C 16X mutation: a case of SF1 haploinsufficiency. J Clin Endocrinol Metab 89: 4829-4832.
15. Achermann JC, Ito M, Ito M, Hindmarsh PC, Jameson JL, 1999 A mutation in the gene encoding steroidogenic factor-1 causes XY sex reversal and adrenal failure in humans. Nat Genet 22: 125-126.
16. Philibert P, Zenaty D, Lin L, et al, 2007 Mutational analysis of steroidogenic factor 1 (NR5a1) in 24 boys with bilateral anorchia: a French collaborative study. Hum Reprod 22: 3255-3261.
17. Köhler B, Lin L, Ferraz-de-Souza B, et al, 2008 Five novel mutations in steroidogenic factor 1 (SF1, NR 5A1) in 46,XY patients with severe underandrogenization but without adrenal insufficiency. Hum Mutat 29: 59-64.
18. Lin L, Achermann JC, 2008 Steroidogenic factor-1 (SF- 1, A d4BP, NR 5A1) and disorders of testis development. Sex Dev 2: 200-209.
19. Biason-Lauber A, Schoenle E J, 2000 A pparently normal ovarian differentiation in a prepubertal girl with transcriptionally inactive steroidogenic factor 1 (NR5A1/SF-1) and adrenocortical insufficiency. Am J Hum Genet 67: 1563-1568.
20. Jeays-Ward K, Hoyle C, Brennan J, et al, 2003 Endothelial and steroidogenic cell migration are regulated by WNT4 in the developing mammalian gonad. Development 130: 3663-3670.
21. Yao HH, Matzuk MM, Jorgez C J, et al, 2004 Follistatin operates downstream of Wnt4 in mammalian ovary organogenesis. Dev Dyn 230: 210-215.
22. Heikkilä M, Prunskaite R, Naillat F, et al, 2005 The partial female to male sex reversal in Wnt-4-deficient females involves induced expression of testosterone biosynthetic genes and testosterone production, and depends on androgen action. Endocrinology 146: 4016-4023.
23. Vainio S, Heikkilä M, Kispert A, Chin N, McMahon AP, 1999 Female development in mammals is regulated by Wnt-4 signalling. Nature 397: 405-409.
24. Philibert P, Biason-Lauber A, Rouzier R, et al, 2008 Identification and functional analysis of a new WNT4 gene mutation among 28 adolescent girls with primary amenorrhea and Müllerian duct abnormalities: a French collaborative study. J Clin Endocrinol Metab 93: 895-900.
25. Biason-Lauber A, Konrad D, Navratil F, Schoenle E J, 2004 A WNT4 mutation associated with Müllerian-duct regression and virilization in a 46,XX woman. N Engl J Med 351: 792-798.
26. Biason-Lauber A, De Filippo G, Konrad D, Scarano G, Nazzaro A, Schoenle E J, 2007 WNT4 deficiency-a clinical phenotype distinct from the classic Mayer-Rokitansky-Küster-Hauser syndrome: a case report. Hum Reprod 22: 224-229.
27. Zanaria E, Muscatelli F, Bardoni B, et al, 1994 An unusual member of the nuclear hormone receptor superfamily responsible for X-linked adrenal hypoplasia congenita. Nature 372: 635-641.
28. Bardoni B, Zanaria E, Guioli S, et al, 1994 A dosage sensitive locus at chromosome Xp21 is involved in male to female sex reversal. Nat Genet 7: 497-501.
29. Seminara SB, Achermann JC, Genel M, Jameson JL, Crowley WF, Jr, 1999 X-linked adrenal hypoplasia congenita: a mutation in DAX1 expands the phenotypic spectrum in males and females. J Clin Endocrinol Metab 84: 4501-4509.
30. Yu RN, Ito M, Saunders TL, Camper SA, Jameson JL, 1998 Role of Ahch in gonadal development and gametogenesis. Nat Genet 20: 353-357.
31. Mizusaki H, Kawabe K, Mukai T, et al, 2003 Dax-1 (dosage-sensitive sex reversal-adrenal hypoplasia congenita critical region on the X chromosome, gene 1) gene transcription is regulated by wnt4 in the female developing gonad. Mol Endocrinol 17: 507-519.
32. Schmidt D, Ovitt CE, Anlag K, et al, 2004 The murine winged-helix transcription factor Foxl2 is required for granulosa cell differentiation and ovary maintenance. Development 131: 933-942.
33. Pailhoux E, Vigier B, Vaiman D, et al, 2002 Ontogenesis of female-to-male sex-reversal in XX polled goats. Dev Dyn 224: 39-50.
34. Beysen D, Vandesompele J, Messiaen L, De Paepe A, De Baere E, 2004 The human FOXL2 mutation database. Hum Mutat 24: 189-193.
35. Crisponi L, Deiana M, Loi A, et al, 2001 The putative forkhead transcription factor FOXL2 is mutated in blepharophimosis/ptosis/epicanthus inversus syndrome. Nat Genet 27: 159-166
36. Uhlenhaut N H, Jakob S, Anlag K, et al, 2009 Somatic sex reprogramming of adult ovaries to testes by FOXL2 ablation. Cell 139: 1130-1142.
37. Kim KA, Zhao J, Andarmani S, et al, 2006 R -Spondin proteins: a novel link to beta-catenin activation. Cell Cycle 5: 23-26.
38. Tomizuka K, Horikoshi K, Kitada R, et al, 2008 R - spondin1 plays an essential role in ovarian development through positively regulating Wnt-4 signaling. Hum Mol Genet 17: 1278-1291.
39. Kocer A, Pinheiro I, Pannetier M, et al, 2008 R -spondin1 and FOXL2 act into two distinct cellular types during goat ovarian differentiation. BMC Dev Biol 8: 36.
40. Parma P, Radi O, Vidal V, et al, 2006 R -spondin1 is essential in sex determination, skin differentiation and malignancy. Nat Genet 38: 1304-1309.
41. Tomaselli S, Megiorni F, De Bernardo C, et al, 2008 Syndromic true hermaphroditism due to an R -spondin1 (RSPO1) homozygous mutation. Hum Mutat 29: 220-226.
42. Krob G, Braun A, Kuhnle U, 1994 True hermaphroditism: geographical distribution, clinical findings, chromosomes and gonadal histology. Eur J Pediatr 153: 2-10.
43. Verkauskas G, Jaubert F, Lortat-Jacob S, Malan V, Thibaud E, Nihoul-Fékété C, 2007 The long-term follow up of 33 cases of true hermaphroditism: a 40-year experience with conservative gonadal surgery. J Urol 177: 726-731.
44. Hadjiathanasiou C G, Brauner R, Lortat-Jacob S, et al, 1994 True hermaphroditism: genetic variants and clinical management. J Pediatr 125: 738-744.
45. Damiani D, Fellous M, McElreavey K, et al, 1997 True hermaphroditism: clinical aspects and molecular studies in 16 cases. Eur J Endocrinol 136: 201-204.
46. Berkovitz GD, Fechner PY, Marcantonio SM, et al, 1992 The role of the sex-determining region of the Ychromosome (SRY) in the etiology of 46,XX true hermaphroditism. Hum Genet 88: 411-416.
47. Ortenberg J, Oddoux C, Craver R, et al, 2002 SRY gene expression in the ovotestes of XX true hermaphrodites. J Urol 167:1828-1831.
48. de la Chapelle A, 1981 The etiology of maleness in XX men. Hum Genet 58: 105-116.
49. López M, Torres L, Méndez JP, et al, 1995 Clinical traits and molecular findings in 46,XX males. Clin Genet 48: 29-34.
50. Vorona E, Zitzmann M, Gromoll J, Schüring AN, Nieschlag E, 2007 Clinical, endocrinological and epigenetic features of the 46,XX male syndrome, compared with 47,XXY Klinefelter patients. J Clin Endocrinol Metab 92: 3458-3465.
51. Abbas N, McElreavey K, Leconiat M, et al, 1993 Familial case of 46,XX male and 46,XX true hermaphrodite associated with a paternal-derived SRY -bearing X chromosome. C R Acad Sci III 316: 375-383.
52. Ergun-Longmire B, Vinci G, Alonso L, et al, 2005 Clinical, hormonal and cytogenetic evaluation of 46,XX males and review of the literature. J Pediatr Endocrinol Metab 18: 739-748.
53. Huang B, Wang S, Ning Y, Lamb AN, Bartley J, 1999 Autosomal XX sex reversal caused by duplication of SOX9. Am J Med Genet 87: 349-353.
54. Seeherunvong T, Perera E M, Bao Y, et al, 2004 46,XX sex reversal with partial duplication of chromosome arm 22q. Am J Med Genet A 127: 149-151.
55. Skordis NA, Stetka DG, MacGillivray MH, Greenfield SP, 1987 Familial 46,XX males coexisting with familial 46,XX true hermaphrodites in same pedigree. J Pediatr 110: 244-248
56. Sarafoglou K, Ostrer H, 2000 Clinical review 111: familial sex reversal: a review. J Clin Endocrinol Metab 85: 483-493.
57. Gore CA, 2010 Neuroendocrine targets of endocrine disruptors. Hormones (Athens) 9: 16-27.
58. Migeon C J, Wisniewski A B, 2003 Human sex differentiation and its abnormalities. Human sex differentiation and its abnormalities. Best Pract Res Clin Obstet Gynaecol 17: 1-18.
59. Meyers C M, Boughman JA, Rivas M, Wilroy R S, Simpson JL, 1996 Gonadal (ovarian) dysgenesis in 46,XX individuals: frequency of the autosomal recessive form. Am J Med Genet 63: 518-524.
60. Pallister PD, Opitz JM, 1979 The Perrault syndrome: autosomal recessive ovarian dysgenesis with facultative, non-sex-limited sensorineural deafness. Am J Med Genet 4: 239-246.
61. Nishi Y, Hamamoto K, Kajiyama M, Kawamura I, 1988 The Perrault syndrome: clinical report and review. Am J Med Genet: 31: 623-629.
62. Aittomäki K, Herva R, Stenman UH, et al, 1996 Clinical features of primary ovarian failure caused by a point mutation in the follicle-stimulating hormone receptor gene. J Clin Endocrinol Metab 81: 3722-3776.
63. Marozzi A, Manfredini E, Tibiletti MG, et al 2000 Molecular definition of Xq common-deleted region in patients affected by premature ovarian failure. Hum Genet 107: 304-311.
64. Rossetti R, Di Pasquale E, Marozzi A, et al, 2009 BMP15 mutations associated with primary ovarian insufficiency cause a defective production of bioactive protein. Hum Mutat 30: 804-810.
65. Murray A, Webb J, Grimley S, Conway G, Jacobs P, 1998 Studies of FRAXA and FRAXE in women with premature ovarian failure. J Med Genet 35: 637-640.
66. Massad-Costa A M, da Silva ID, Affonso R, et al, 2007 Gene analysis in patients with premature ovarian failure or gonadal dysgenesis: a preliminary study. Maturitas 57: 399-404.
67. Holland C, 2000 47,XXX in an adolescent with premature ovarian failure and autoimmune disease. J Pediatr Adolesc Gynecol 13: 93.
68. Schlessinger D, Herrera L, Crisponi L, Mumm S, Percesepe A, Pellegrini M, 2002 Genes and translocations involved in POF. Am J Med Genet 111: 328-333.
69. Dacou-Voutetakis C, Maniati-Christidi M, Dracopoulou-Vabouli M, 2001 Genetic aspects of congenital adrenal hyperplasia. J Pediatr Endocrinol Metab 14: Suppl 5: 1303-1308.
70. Krone N, Dhir V, Ivison HE, Arlt W, 2007 Congenital adrenal hyperplasia and P450 oxidoreductase deficiency. Clin Endocrinol (Oxf) 66: 162-172.
71. Merke DP, Bornstein SR, 2005 Congenital adrenal hyperplasia. Lancet 365: 2125-2136.
72. Tonetto-Fernandes V, Lemos-Marini SH, Kuperman H, Ribeiro-Neto L M, Verreschi IT, Kater CE, 2006 Serum 21-Deoxycortisol, 17-Hydroxyprogesterone, and 11- deoxycortisol in classic congenital adrenal hyperplasia: clinical and hormonal correlations and identification of patients with 11beta-hydroxylase deficiency among a large group with alleged 21-hydroxylase deficiency. J Clin Endocrinol Metab 91: 2179-2184.
73. Moran C, Azziz R, Carmina E, et al, 2000 21-Hydroxylase deficient nonclassic adrenal hyperplasia is a progressive disorder: a multicenter study. A m J Obstet Gynecol 183: 1468-1474.
74. Dacou-Voutetakis C, Dracopoulou M, 1999 High incidence of molecular defects of the CY P21 gene in patients with premature adrenarche. J Clin Endocrinol Metab 84: 1570-1574.
75. Dracopoulou-Vabouli M, Maniati-Christidi M, Dacou-Voutetakis C, 2001 The spectrum of molecular defects of the CY P21 gene in the Hellenic population: variable concordance between genotype and phenotype in the different forms of congenital adrenal hyperplasia. J Clin Endocrinol Metab 86: 2845-2848.
76. Joehrer K, Geley S, Strasser-Wozak E M, et al, 1997 CYP11B1 mutations causing non-classic adrenal hyperplasia due to 11 beta-hydroxylase deficiency. Hum Mol Genet 6: 1829-1834.
77. Scott RR, Miller WL, 2008 Genetic and Clinical Features of P450 O xidoreductase Deficiency. Horm Res 69: 266-275.
78. Arlt W, Walker EA, Draper N, et al, 2004 C ongenital adrenal hyperplasia caused by mutant P450 oxidoreductase and human androgen synthesis: analytical study. Lancet 363: 2128-2135.
79. Mendonca BB, Leite MV, de Castro M, et al, 2002 Female pseudohermaphroditism caused by a novel homozygous missense mutation of the GR gene. J Clin Endocrinol Metab 87: 1805-1809.
80. Charmandari E, Kino T, Ichijo T, Chrousos GP, 2008 Generalized Glucocorticoid Resistance: Clinical Aspects, Molecular Mechanisms and Implications of a Rare Genetic Disorder. J Clin Endocrinol Metab 93: 1563-1572.
81. Payne A H, Hales DB, 2004 Overview of steroidogenic enzymes in the pathway from cholesterol to active steroid hormones. Endocr Rev 25: 947-970.
82. Mullis PE, Yoshimura N, Kuhlmann B, Lippuner K, Jaeger P, Harada H, 1997 A romatase deficiency in a female who is compound heterozygote for two new point mutations in the P450arom gene: impact of estrogens on hypergonadotropic hypogonadism, multicystic ovaries, and bone densitometry in childhood. J Clin Endocrinol Metab 82: 1739-1745.
83. Belgorosky A, Pepe C, Marino R, et al, 2003 Hypothalamic- pituitary-ovarian axis during infancy, early and late prepuberty in an aromatase-deficient girl who is a compound heterozygote for two new point mutations of the CY P19 gene. J Clin Endocrinol Metab 88: 5127-5131.
84. Lin L, Ercan O, Raza J, et al, 2007 Variable phenotypes associated with aromatase (CY P19) insufficiency in humans. J Clin Endocrinol Metab 92: 982-990.
85. Masi L, Becherini L, Gennari L, et al, 2001 Polymorphism of the aromatase gene in postmenopausal Italian women: distribution and correlation with bone mass and fracture risk. J Clin Endocrinol Metab 86: 2263-2269.
86. Petry C J, Ong KK, Michelmore KF, et al, 2005 Association of aromatase (CYP 19) gene variation with features of hyperandrogenism in two populations of young women. Hum Reprod 20: 1837-1843.
87. Kirk JMW, Perry LA, Shand WS, Kirby R S, Besser GM, Savage MO, 1990 Female pseudohermaphroditism due to a maternal adrenocortical tumor. J Clin Endocrinol Metab 70: 1280-1284.
88. Vauthier-Brouzes D, Vanna Lim-You K, Sebagh E, Lefebvre G, Darbois Y, 1997 Krukenberg tumor during pregnancy with maternal and fetal virilization: a difficult diagnosis. A case report. J Gynecol O bstet Biol R eprod (Paris) 26: 831-833.
89. Mazza V, Di Monte I, Ceccarelli PL, et al, 2002 Prenatal diagnosis of female pseudohermaphroditism associated with bilateral luteoma of pregnancy: case report. Hum Reprod 17: 821-824.
90. Kai H, Nose O, Iida Y, Ono J, Harada T, Yabuuchi H, 1979 Female pseudohermaphroditism caused by maternal congenital adrenal hyperplasia. J Pediatr 95: 418-420.
91. Lo JC, Schwitzgebel VM, Tyrrell JB, et al, 1999 Normal female infants born of mothers with classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency. J Clin Endocrinol Metab 84: 930-936.
92. Morcel K, Camborieux L; Programme de Recherches surles Aplasies Müllιriennes, Guerrier D, 2007 Mayer-Rokitansky-Küster-Hauser (MRKH) syndrome. Orphanet J Rare Dis 2: 13.
93. Achermann JC, Hughes IA, 2008 Disorders of sex development. In: Kronenberg HM, Melmed S, Polonsky KS, Larsen PR (eds) Williams Textbook of Endocrinology 11th edition, Philadelphia; pp, 783-848.